Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Real-World Clinical Profile of Patients Prescribed Evolocumab in Japan | Synapse

February 29, 2024Open Access

Ver artículo completo

Real-World Clinical Profile of Patients Prescribed Evolocumab in Japan

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Real-world utilization data for evolocumab, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be introduced in Japan in 2016, to date are limited. This study aimed to clarify the current real-world patient user profiles of evolocumab based on large-scale health claims data.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Feng et al. (Thu,) studied this question.

synapsesocial.com/papers/68e76d08b6db6435876e2e56 https://doi.org/https://doi.org/10.1253/circj.cj-23-0814

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Context and Considerations for Use of Two Japanese Real-World Databases in Japan: Medical Data Vision and Japanese Medical Data Center2022 · 108 citations
2Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions2016 · 1,477 citations
3Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study2022 · 43 citations
4Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan2023 · 37 citations
5Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial2019 · 29 citations